On or around 11/13/2019 (Date of last review)
Filing Date: November 05, 2019
According to the Complaint, Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases.
This action stems from a proposed transaction announced on October 10, 2019, pursuant to which Ra Pharmaceuticals, Inc. will be acquired by UCB S.A.
On October 9, 2019, Ra Pharmaceuticals’ Board of Directors caused the Company to enter into an agreement and plan of merger with UCB. Pursuant to the terms of the Merger Agreement, Ra Pharmaceuticals’ stockholders will receive $48.00 in cash for each share of Ra Pharmaceuticals common stock they own.
On November 1, 2019, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.
Company & Securities Information
Defendant: Ra Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: RARX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Earl M. Wheby, Jr., et al. v. Ra Pharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 19-CV-02099
JUDGE: Hon. Leonard P. Stark
DATE FILED: 11/05/2019
CLASS PERIOD START: 10/10/2019
CLASS PERIOD END: 11/05/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available